RxDoctor Payments DataLook up a doctor →

Gazala Khan, MD

Internal Medicine · Ann Arbor, MINPI 1407978513

Payments from drug & device makers

$1,954,260in general payments, 2019–2025

Across 224 payments — averaging $8724.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$949K
  • Ipsen Bioscience Inc.$369K
  • Taiho Oncology, Inc.$115K
  • Amgen$87K
  • Ipsen Biopharmaceuticals, Inc$76K
  • Incyte Corporation$73K
  • plus $284K from 11 others

What the payments were for

  • Consulting fees$26,80831%
  • Speaking & faculty fees$52,71361%
  • Travel & lodging$4,3405%
  • Food & beverage$2,1873%
  • Education$850%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,954,260 in reported general payments places this provider in the 95th percentile of 4,567 internal medicine providers in Michigan.

See all internal medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$42,719
Medicare patients
110
Services billed
369

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CabometyxCabozantinib S-Malate25$498,496
GleevecImatinib Mesylate11$213,924
XermeloTelotristat Etiprate11$104,668
CreonLipase/Protease/Amylase18$29,122
EliquisApixaban14$7,429
Prochlorperazine Maleate52$1,029
Ondansetron OdtOndansetron37$736
Lidocaine-PrilocaineLidocaine/Prilocaine28$307
Potassium Chloride11$206
Duloxetine Hcl15$195
Oxycodone Hcl18$180
Pantoprazole Sodium14$179
Dexamethasone15$160
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen13$154
Amlodipine Besylate14$103

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Exelixis Inc.Cabometyx$4,335$498,49625 claims
NovartisGleevec$328$213,92411 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,567 internal medicine providers in Michigan.

Other internal medicine in Ann Arbor

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →